Last reviewed · How we verify
Human Papillomavirus Tumor Antigen Vaccine
Human Papillomavirus Tumor Antigen Vaccine is a Vaccine Biologic drug developed by Michael K. Gibson. It is currently in Phase 2 development for Prevention of cervical, vulvar, vaginal, penile, and anal cancers caused by Human Papillomavirus.
Stimulates an immune response against Human Papillomavirus (HPV) tumor antigens
Stimulates an immune response against Human Papillomavirus (HPV) tumor antigens Used for Prevention of cervical, vulvar, vaginal, penile, and anal cancers caused by Human Papillomavirus.
At a glance
| Generic name | Human Papillomavirus Tumor Antigen Vaccine |
|---|---|
| Sponsor | Michael K. Gibson |
| Drug class | Vaccine |
| Modality | Biologic |
| Therapeutic area | Vaccines |
| Phase | Phase 2 |
Mechanism of action
This vaccine works by introducing HPV tumor antigens to the body, which triggers an immune response and helps to prevent HPV-related diseases.
Approved indications
- Prevention of cervical, vulvar, vaginal, penile, and anal cancers caused by Human Papillomavirus
Common side effects
- Pain, redness, swelling, or itching at the injection site
- Fatigue
- Headache
Key clinical trials
- TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers (PHASE1, PHASE2)
- E7 TCR T Cells for Human Papillomavirus-Associated Cancers (PHASE1, PHASE2)
- Clinical Trial Assessing the Safety and Immunologic Correlates of Heterologous Prime-Boost With pNGVL4a-Sig/E7(Detox)/HSP70 and TA-HPV in Healthy Donors Followed by Peripheral Blood Collection (PHASE1)
- A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer (PHASE1, PHASE2)
- A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer (PHASE1, PHASE2)
- pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer (PHASE2)
- A Clinical Trial to Assess PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients (PHASE1)
- A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Human Papillomavirus Tumor Antigen Vaccine CI brief — competitive landscape report
- Human Papillomavirus Tumor Antigen Vaccine updates RSS · CI watch RSS
- Michael K. Gibson portfolio CI
Frequently asked questions about Human Papillomavirus Tumor Antigen Vaccine
What is Human Papillomavirus Tumor Antigen Vaccine?
How does Human Papillomavirus Tumor Antigen Vaccine work?
What is Human Papillomavirus Tumor Antigen Vaccine used for?
Who makes Human Papillomavirus Tumor Antigen Vaccine?
What drug class is Human Papillomavirus Tumor Antigen Vaccine in?
What development phase is Human Papillomavirus Tumor Antigen Vaccine in?
What are the side effects of Human Papillomavirus Tumor Antigen Vaccine?
Related
- Drug class: All Vaccine drugs
- Manufacturer: Michael K. Gibson — full pipeline
- Therapeutic area: All drugs in Vaccines
- Indication: Drugs for Prevention of cervical, vulvar, vaginal, penile, and anal cancers caused by Human Papillomavirus
- Compare: Human Papillomavirus Tumor Antigen Vaccine vs similar drugs
- Pricing: Human Papillomavirus Tumor Antigen Vaccine cost, discount & access